Patents by Inventor Andrew A. Wolff

Andrew A. Wolff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method and composition for restoring diuretic and renal function
    Publication number: 20050038017
    Abstract: Methods and compositions for restoring diuretic and renal function
    Type: Application
    Filed: September 29, 2004
    Publication date: February 17, 2005
    Inventors: Andrew Wolff, George Schreiner, Evan Beckman, Glenn Smits
  • Sustained release ranolazine formulations
    Patent number: 6852724
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 850 and 4000 ng base/mL.
    Type: Grant
    Filed: March 5, 2003
    Date of Patent: February 8, 2005
    Assignee: CV Therapeutics, Inc.
    Inventor: Andrew A. Wolff
  • Method and composition for restoring diuretic and renal function
    Patent number: 6818647
    Abstract: Methods and compositions for restoring diuretic and renal function.
    Type: Grant
    Filed: May 16, 2002
    Date of Patent: November 16, 2004
    Assignee: CV Therapeutics, Inc
    Inventors: Andrew A. Wolff, George F. Schreiner
  • Sustained release ranolazine formulations
    Publication number: 20040097514
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
    Type: Application
    Filed: July 7, 2003
    Publication date: May 20, 2004
    Inventors: Andrew A. Wolff, Fiona Baker, John Richard Langridge
  • Method of treating diabetes
    Publication number: 20040063717
    Abstract: Methods are provided for treating diabetes, lowering plasma level of HbA1c, glucose plasma levels, total cholesterol plasma level, and/or triglyceride plasma level while increasing HDL cholesterol levels and delaying onset of diabetic retinopathy in a diabetic, pre-diabetic, or non-diabetic mammal while minimizing undesirable side effects.
    Type: Application
    Filed: May 21, 2003
    Publication date: April 1, 2004
    Inventors: Andrew Wolff, Markus Jerling
  • Sustained release ranolazine formulations
    Publication number: 20040029890
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/nL.
    Type: Application
    Filed: July 7, 2003
    Publication date: February 12, 2004
    Applicant: CV Therapeutics, Inc.
    Inventors: Andrew A. Wolff, Fiona Baker, John Richard Langridge
  • Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
    Patent number: 6677342
    Abstract: Methods are disclosed for treating congestive heart failure with partial inhibitors of fatty acid oxidation. The compounds increase cardiac performance without affecting heart rate, blood pressure, or oxygen consumption.
    Type: Grant
    Filed: August 27, 2002
    Date of Patent: January 13, 2004
    Assignee: CV Therapeutics, Inc.
    Inventors: Andrew A. Wolff, Brent Blackburn, Hani Naief Sabbah, William Clark Stanley
  • Sustained release ranolazine formulations
    Patent number: 6620814
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: September 16, 2003
    Assignee: CV Therapeutics, Inc.
    Inventors: Andrew A. Wolff, Fiona Baker, John Langridge
  • Sustained release ranolazine formulations
    Patent number: 6617328
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: September 9, 2003
    Assignees: CV Therapeutics, Inc, Syntex (USA), LLC
    Inventors: Andrew A. Wolff, Fiona Baker, John Langridge
  • Sustained release ranolazine formulations
    Publication number: 20030166659
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 850 and 4000 ng base/mL.
    Type: Application
    Filed: March 5, 2003
    Publication date: September 4, 2003
    Inventor: Andrew A. Wolff
  • Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
    Publication number: 20030119718
    Abstract: Methods are disclosed for treating congestive heart failure with partial inhibitors of fatty acid oxidation. The compounds increase cardiac performance without affecting heart rate, blood pressure, or oxygen consumption.
    Type: Application
    Filed: August 27, 2002
    Publication date: June 26, 2003
    Applicant: CV Therapeutics, Inc.
    Inventors: Andrew A. Wolff, Brent Blackburn, Hani Naief Sabbah, William Clark Stanley
  • Sustained release ranolazine formulations
    Publication number: 20030100566
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
    Type: Application
    Filed: September 27, 2002
    Publication date: May 29, 2003
    Applicant: CV Therapeutics, Inc.
    Inventors: Andrew A. Wolff, Fiona Baker, John Richard Langridge
  • Sustained release ranolazine formulations
    Publication number: 20030099705
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
    Type: Application
    Filed: September 27, 2002
    Publication date: May 29, 2003
    Applicant: CV Therapeutics, Inc.
    Inventors: Andrew A. Wolff, Fiona Baker, John Richard Langridge
  • Method and composition for restoring diuretic and renal function
    Publication number: 20030096810
    Abstract: Methods and compositions for restoring diuretic and renal function
    Type: Application
    Filed: May 16, 2002
    Publication date: May 22, 2003
    Inventors: Andrew A. Wolff, George F. Schreiner, Evan Beckman, Glenn Smits
  • Sustained release ranolazine formulations
    Patent number: 6562826
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 850 and 4000 ng base/mL.
    Type: Grant
    Filed: September 25, 2002
    Date of Patent: May 13, 2003
    Assignee: CV Therapeutics, Inc.
    Inventor: Andrew A. Wolff
  • Method of treating arrhythmias
    Patent number: 6537974
    Abstract: A method for treating arrhythmia in mammals is provided comprising administering a low dose of an adenosine receptor agonist of the Formula I: wherein R1 is an optionally substituted heterocyclic group, preferably monocyclic.
    Type: Grant
    Filed: September 7, 2001
    Date of Patent: March 25, 2003
    Assignee: CV Therapeutics, Inc.
    Inventor: Andrew Wolff
  • Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
    Patent number: 6528511
    Abstract: Methods are disclosed for treating congestive heart failure with partial inhibitors of fatty acid oxidation. The compounds increase cardiac performance without affecting heart rate, blood pressure, or oxygen consumption.
    Type: Grant
    Filed: February 15, 2001
    Date of Patent: March 4, 2003
    Assignee: CV Therapeutics, Inc.
    Inventors: Andrew A. Wolff, Brent Blackburn, Hani Naief Sabbah, William Clark Stanley
  • Sustained release ranolazine formulations
    Patent number: 6525057
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
    Type: Grant
    Filed: August 9, 2001
    Date of Patent: February 25, 2003
    Assignee: CV Therapeutics, Inc.
    Inventors: Andrew A. Wolff, Fiona Baker, John Langridge
  • Sustained release ranolazine formulations
    Patent number: 6503911
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
    Type: Grant
    Filed: October 19, 2001
    Date of Patent: January 7, 2003
    Assignees: CV Therapeutics, Inc., Syntex USA, Inc.
    Inventors: Andrew A. Wolff, Fiona Baker, John Langridge
  • Methods for treating angina with ranolazine
    Patent number: 6479496
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 850 and 4000 ng base/mL.
    Type: Grant
    Filed: March 8, 2000
    Date of Patent: November 12, 2002
    Assignee: CV Therapeutics, Inc.
    Inventor: Andrew A. Wolff